Merck: Don't Fight The Tape, How Low Can It Go?
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.
Merck Is Suffering From a Classic Pharma Problem
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
STAT1d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
FiercePharma1d
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
StockStory.org on MSN1d
Why Merck (MRK) Stock Is Falling Today
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed ...